TB-500 / BPC-157 is a dual-peptide research formulation pairing two of the most extensively studied tissue-active peptides in the contemporary research literature. This pre-formulated blend of thymosin beta-4 fragment (TB-500) and Body Protection Compound-157 (BPC-157) enables investigations into potential synergistic or additive interactions between these two mechanistically distinct peptide sequences within a single experimental system.
TB-500, derived from the actin-binding domain of thymosin beta-4, is primarily studied for its effects on cytoskeletal dynamics, cellular migration, and angiogenesis in vitro. BPC-157 has been investigated for its roles in fibroblast proliferation, growth factor receptor modulation, and nitric oxide system regulation. The combination format addresses a growing trend in peptide research toward multi-component experimental designs that more closely approximate the complex peptide milieu found in biological systems. Researchers can utilize this formulation to compare single-agent versus combination effects on endpoint measures including cell viability, migration distance, tube formation, and gene expression profiles.
Each lot is produced under controlled conditions with full analytical testing and is accompanied by a certificate of analysis. Ares Research supplies this formulation exclusively for in vitro laboratory research. It is not intended for human or veterinary use.
FDA Disclaimer
The information presented on this website has not been evaluated by the U.S. Food and Drug Administration. No content on this site, nor any product listed, is intended to diagnose, treat, cure, or prevent any disease or medical condition.
All products are supplied solely as laboratory research reagents and are not for human consumption. Ares Research does not supply products to patients and makes no representations regarding therapeutic or medical use.
Ares Research operates as a chemical supplier only. It is not a compounding pharmacy and does not function as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.
